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The most recently identified human herpesvirus, Kaposi’s
sarcoma (KS)-associated herpesvirus (KSHV) or human her-
pesvirus 8 (HHV-8), has been found to be a necessary, al-
though perhaps not sufficient, etiologic agent for all forms
of KS (1, 2). This virus is also invariably present in a rare
subset of malignant lymphomas, primary effusion lympho-
mas (PELs), and in a significant percentage of patients with
multicentric Castleman’s disease, an angiolymphoprolifera-
tive disorder (3, 4). Both KS and PEL occur more frequently,
but not exclusively, in HIV-infected individuals, and all cases
of HIV-related multicentric Castleman’s disease are infected
with KSHV. These findings suggest an important role of
immunosuppression and HIV infection in KSHV-mediated
pathogenesis. Although it remains controversial whether
KS is a malignant neoplasm, KS lesions probably evolve from
a reactive, inflammatory/angioproliferative process into true
clonal cancers. Thus, KS is generally considered a malig-
nancy, especially because of its frequent multifocal and ag-
gressive behavior. Given the definitive association of KSHV
with two different human malignancies, it is not difficult to
consider KSHV to be a human oncogenic virus.
 
KSHV is a gammaherpesvirus that is homologous
 
 
 
to
EBV and herpesvirus saimiri (HVS), human and simian vi-
ruses, respectively, that are able to transform lymphoid cells
in culture and cause malignant lymphomas in some cir-
cumstances. Genomic sequencing has revealed that KSHV
contains several genes with likely oncogenesis-related func-
tions that subvert pathways involved in cellular activation,
proliferation, differentiation, and survival. Many of these
genes are viral homologues of cellular genes, including
those encoding viral cyclin D, IFN regulatory factors
(IRFs), viral IL-6 (vIL-6), BCL-2, FLICE-inhibitory pro-
tein (FLIP), three chemokines (viral macrophage inflam-
matory protein [vMIP]-I, -II, and -III) and last, but not
least, a G protein–coupled receptor (KSHV GPCR). Three
of these genes have been found to be transforming in
mouse fibroblast assays (vIRF, KSHV GPCR, and vIL-6),
and two are homologous to cellular oncogenes (vBCL-2
and v-cyclin D). Two additional viral genes having no di-
rect cellular counterpart, those encoded by open reading
frame K1 (containing an immunoreceptor tyrosine-based ac-
tivation motif [ITAM]) and K12, have also been found to be
transforming in certain experimental assays. Therefore, KSHV
qualifies as the virus with the most putative oncogenes iden-
tified to date. Thus, the following dilemma: why are KSHV-
associated neoplasms so rare in the general population in
spite of a seroprevalence of KSHV infections of at least 5%
in Western countries? Why is KSHV only poorly trans-
forming after infecting cells in culture? This may be par-
tially explained by the concept that KSHV-mediated patho-
genesis will be determined by the specific pattern of viral
gene expression and the specific cellular background in
which these genes are expressed, both of which are highly
dependent on host factors (5, 6). Most of the genes found
or suspected to be transforming are lytic genes, which are
only transcribed in a subset of cells in KS lesions and PEL.
However, the pathogenic potential of a single gene product
thus sparsely expressed is elegantly demonstrated in the ar-
ticle by Yang et al. in this issue (7).
The report by Yang et al. provides the first transgenic
mouse model for KS using a single KSHV gene, the
chemokine receptor KSHV GPCR. In this study, it was
found that expression of KSHV GPCR in hematopoietic
cells of transgenic mice leads to angioproliferative lesions
that exhibit most of the characteristics of KS. This viral re-
ceptor is encoded by open reading frame 74, and has closest
homology to human IL-8 receptors type A (CXC chemo-
kine receptor 1 [CXCR1]) and B (CXCR2) (8). KSHV
GPCR is a constitutively signaling receptor that can bind
chemokines from the CXC and the CC families, but does
not require ligand for its activation (9). However, specific
chemokines can further enhance and others inhibit this
constitutive activity (10–12). KSHV GPCR has been found
to have several unique properties among viral chemokine
receptors, besides its ligand-independent activity. KSHV
GPCR has been demonstrated to be transforming when
transfected into NIH-3T3 cells (13). In addition, and per-
haps more important to the pathogenesis of KS than a di-
rect oncogenic role, it was shown that signaling by KSHV
GPCR leads to the upregulation of expression of vascular
endothelial growth factor (VEGF), thereby inducing angio-
genesis via a paracrine mechanism(s) (13).
In addition
 
 
 
to the chemokine receptor KSHV GPCR,
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KSHV encodes three chemokine ligands with interesting
functional characteristics. vMIP-I and -II can promote an-
giogenesis (14). vMIP-II has been shown to inhibit HIV
infection in vitro (15). Both vMIP-I and -II can bind the
human CC chemokine receptor 8 (CCR8). vMIP-I acts as
an agonist (16, 17) of CCR8. vMIP-II has been suggested
to behave as an antagonist (16) or as an agonist and Th2
lymphocyte chemoattractant (18) by two different groups
of investigators. As CCR8 is preferentially expressed in Th2
lymphocytes, expression of these viral chemokines may have
immunomodulatory effects, perhaps mediating some of the
inflammatory aspects of KS. vMIP-II can also inhibit sig-
naling of KSHV GPCR, perhaps providing this virus with
an additional control or feedback mechanism (11). Other
examples of chemokines and chemokine receptors encoded
by herpesviruses include two CXC chemokines encoded
by CMV genes UL146 and UL147. vCXC-1 (UL146) has
chemotactic activity for neutrophils similar to that of hu-
man IL-8. This suggests that vCXC-1 may be involved in
dissemination during acute infection and may account for
the presence of neutrophils in CMV disease (19). CMV also
encodes three proteins with homology to CC chemokine
receptors (US27, US28, and UL33), which are thought to
be able to sequester cellular chemokines (20). HHV-6 also
encodes chemokine (U83 [21]) and chemokine receptor
(U12 and U51) homologues (22). Interestingly, EBV lacks
viral chemokine receptor or chemokine homologues, but it
can induce the cellular expression of both (23–25). Simi-
larly, herpes simplex virus can activate a variety of cellular
chemokines involved in its pathogenesis (26). Many animal
herpesviruses have also pirated chemokine and chemokine
receptor genes. Therefore, it is common for herpesviruses
to use this family of receptor–ligand signaling pathways for
their propagation and subversion of immune responses. In
addition, a novel mechanism for subversion of chemokine
responses by a herpesvirus has recently been identified, and
is reported in this issue by Parry et al. (27). It involves the
production of a secreted protein by the murine gammaher-
pesvirus 68, which can bind and sequester a variety of
chemokines in spite of having no sequence similarity to
chemokine receptors.
It has been suggested
 
 
 
that stimulation of angiogenesis via
paracrine mechanisms is important in KSHV-mediated
pathogenesis
 
 
 
(13, 28).
 
 
 
This idea is supported by observations
made after in vitro KSHV infection of primary human en-
dothelial cell cultures (29). Infection of these cultures by
KSHV results in dramatic phenotypical changes. These in-
clude a change from a cobblestone to a spindle cell mor-
phology, greatly prolonged life span verging on immortal-
ization, expression of telomerase, and colony formation in
soft agar. In addition, infection by KSHV results in the sus-
tained upregulation of VEGF receptor 2 (VEGFR-2, KDR,
flk-1), the principal mitogenic receptor for VEGF. The
surprising finding was that KSHV could only be found in a
small proportion (5–10%) of the cells in these cultures. Su-
pernatants from infected cultures exhibit some of the effects
of actual infection such as upregulation of VEGFR-2 ex-
pression, suggesting involvement of paracrine mechanisms
 
leading to the continuous and unregulated proliferation of
endothelial cells in culture.
Although KSHV GPCR has been demonstrated to in-
duce cellular proliferation and transformation when over-
expressed in murine cells, and KSHV has been found to be
transforming in endothelial cell cultures, the paper by Yang
et al. (7) provides the first evidence that a KSHV gene can
induce angioproliferative lesions in animals. In addition, the
pathology obtained in the KSHV GPCR transgenic mice is
remarkably similar to KS, with angiogenesis and CD34
 
1
 
spindle cell proliferation. Interestingly, the KS-like angio-
proliferative lesions were obtained when the transgene was
placed under the control of a CD2 promoter, and expressed
by T and NK cells. These KSHV GPCR–expressing cells
were found to infiltrate the lesions, and have a similar dis-
tribution as cells expressing VEGF. Therefore, the authors
suggested that KSHV GPCR is not directly transform-
ing, but rather can activate the expression of cellular fac-
tors, in particular VEGF, that in turn recruit and stimu-
late the proliferation of endothelial and spindle cells, thereby
inducing the formation of KS-like lesions (Fig. 1). While
the selection of a CD2 promoter was somewhat arbitrary,
the resulting expression of KSHV GPCR in only a few
cells in the lesions in the transgenic mice may be similar to
KSHV GPCR expression within KS lesions in humans.
 
 
 
In
lymphoma cell lines, KSHV GPCR exhibits
 
 
 
an early lytic
pattern of expression (30, 31). In KS lesions, there is a small
subset of cells expressing lytic genes that appear to be pro-
ductively infected with KSHV (32, 33), and according to
one recent report (24), KSHV GPCR is expressed by these
scattered cells. Therefore, since in this novel mouse model
KSHV GPCR expression in a few infiltrating cells is able to
recapitulate the induction of angioproliferative lesions re-
sembling KS, it can be argued that in KS lesions the expres-
sion of this viral receptor by a subset of infected cells could
have a major contribution to KSHV-induced angiogenesis.
This finding suggests that KSHV GPCR is a critical viral
gene involved in the pathogenesis of KS, and points to the
dramatic effect of paracrine stimulation of angiogenesis me-
diated by VEGF secretion in KS pathogenesis.
Yang et al. (7) suggest that while KSHV GPCR is in-
volved in induction of proliferative lesions in the transgenic
animals, it functions primarily by “paracrine” mechanisms. Al-
though the CD2-driven KSHV GPCR was expressed by T
and NK cells in lymphoid organs, no lymphoproliferative
diseases were identified. This implies that while KSHV
GPCR can induce transformation of immortalized mouse
fibroblasts, it may not cause mouse T cell proliferation and
transformation, arguing either for cell type specificity or for
the requirement of additional genetic events for transfor-
mation. However, an explanation based solely on a mecha-
nism mediated by VEGF secretion by KSHV GPCR–
expressing T cells does not explain two important features
of this model: Why are angioproliferative lesions caused by
excess VEGF production not observed in lymphoid organs?
And why do these T cells infiltrate certain sites in which
they are able to survive long enough to induce an angio-
proliferative lesion? These facts suggest that the KSHV 
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GPCR–expressing T cells in the lesions are functionally
different from their counterparts in lymphoid organs and
peripheral circulation. This difference may be conferred by
recruitment and activation at sites of inflammation, which
may also explain the preferential development of KS-like
lesions in skin and mucosal sites in the transgenic mice.
However, alternative but more speculative models can be
proposed. As KSHV GPCR is transforming, at least in the
NIH-3T3 model of oncogenesis, it may as well cause sto-
chastic genetic alterations in cells in which it is expressed.
In the transgenic T cell population, it could lead to a trans-
formed phenotype with particular homing, survival, and
VEGF-secreting characteristics. These transformed T cells
could infiltrate tissues where they might give rise to tumors
in a paracrine fashion, resembling Hodgkin’s disease, in
which a few transformed Reed-Sternberg cells can support
a dramatic proliferation of reactive lymphoid cells. Another
alternative explanation for the findings by Yang et al. is the
possible transient nature of the expression of the transgene
in endothelial or KS spindle cell precursors, during which
time it might have induced cellular genetic changes suffi-
cient for subsequent tumor development. This possibility is
supported by the finding that hematopoietic and endothe-
lial cells have a common precursor (34, 35). There is no in-
formation available regarding CD2 expression by murine
hemangioblasts, and it may therefore be hypothesized that
as these cells differentiate, CD2 and, in the transgenic ani-
mals, KSHV GPCR, are no longer expressed. This is a
mechanism well documented for human T lymphotropic
virus 1 (HTLV-1), where the major transforming protein,
Tax, is only expressed in early stages of tumor formation
and is not required in established T cell malignancies. Such
“hit and run” explanations have also been proposed for CMV
and EBV (36, 37). Therefore, a more direct, although tran-
sitory role for KSHV GPCR in transformation cannot be
definitely excluded. In KS lesions in humans, KSHV can be
identified in practically all tumor cells, as assessed by latent
gene expression (38, 39), suggesting a requirement for the
virus for tumor maintenance in vivo, in contrast to the mu-
rine model. However, KS cell lines “lose” the viral genome
after several passages in vitro, and three fully transformed
and tumorigenic cell lines have been obtained from KS le-
sions that lack KSHV (40, 41). These findings are consis-
tent with the idea that KSHV-independent mechanisms
can support the growth of KS cells in culture, probably af-
ter KSHV-induced cellular genetic alterations.
The ability of a single KSHV gene, KSHV GPCR, to
recapitulate KS-like pathogenesis when expressed by a
small subset of tumor infiltrating lymphocytes strongly points
to a role for this, and perhaps other lytically expressed
KSHV genes, in the pathogenesis of KS. The findings re-
ported by Yang et al. provide the first KSHV gene trans-
genic mouse model of KS and a fascinating model of para-
crine neoplasia and angioproliferative disorders.
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